Treatment of primary in metastatic prostate cancer: what is the standard of care?
|dc.identifier.citation||Joseph N, Anjanappa M, Choudhury A. Treatment of Primary in Metastatic Prostate Cancer: What Is the Standard of Care? Cancer J. 2020;26(1):83-6.||en|
|dc.description.abstract||Until recently, men with metastatic prostate cancer were commenced on androgen deprivation therapy at diagnosis, followed by sequential lines of treatment with the development of castration resistance. However, the results of recent clinical trials, which revealed that the addition of radiotherapy to the prostate to a dose of 55 to 60 Gy in 20 fractions over 4 weeks in patients with low-volume metastatic hormone-sensitive prostate cancer, in addition to androgen deprivation therapy and another systemic treatment option, either docetaxel, abiraterone, enzalutamide, or apalutamide, has led to a paradigm change in the management of this disease.||en|
|dc.title||Treatment of primary in metastatic prostate cancer: what is the standard of care?||en|
|dc.contributor.department||Ministry of HealthSri Lanka Cancer Research Group, Sri Lanka College of Oncologists, Colombo, Sri Lanka,||en|